Russell Investments Group Ltd. Sells 289,072 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Russell Investments Group Ltd. significantly reduced its stake in TransMedics Group by 97.6%, selling 289,072 shares, and now holds just 6,963 shares worth approximately $468,000.
• Several other institutional investors increased their stakes in TransMedics during the same period, with HighTower Advisors LLC raising its holdings by 137.7% and Public Sector Pension Investment Board increasing its position by 27.4%.
• TransMedics Group reported strong quarterly earnings, with $0.92 earnings per share, exceeding analysts' expectations, and generated revenue of $157.37 million, a 37.7% increase year-over-year.

Russell Investments Group Ltd. decreased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 97.6% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,963 shares of the company's stock after selling 289,072 shares during the quarter. Russell Investments Group Ltd.'s holdings in TransMedics Group were worth $468,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Braidwell LP purchased a new position in shares of TransMedics Group during the 4th quarter valued at $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in TransMedics Group by 16.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock worth $56,307,000 after purchasing an additional 128,474 shares in the last quarter. Mackenzie Financial Corp lifted its stake in TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after purchasing an additional 349,403 shares in the last quarter. Emerald Advisers LLC lifted its stake in TransMedics Group by 22.4% in the 1st quarter. Emerald Advisers LLC now owns 454,794 shares of the company's stock worth $30,599,000 after purchasing an additional 83,083 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in TransMedics Group by 12.7% in the 4th quarter. Northern Trust Corp now owns 354,622 shares of the company's stock worth $22,111,000 after purchasing an additional 40,093 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on TMDX shares. Wall Street Zen cut shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Morgan Stanley boosted their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Oppenheimer boosted their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.11.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Price Performance

Shares of NASDAQ TMDX traded down $0.04 during mid-day trading on Friday, hitting $104.01. 996,736 shares of the company's stock traded hands, compared to its average volume of 877,429. The company's 50-day moving average is $118.07 and its two-hundred day moving average is $104.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The company has a market capitalization of $3.55 billion, a P/E ratio of 53.89 and a beta of 2.18. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $169.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.